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Background: In the past several decades, Polygonum viviparum L. (PV) was reported to have antibacterial, antiulcer,
antioxidant, antitumor, anti-inflammatory, and antiarthritic properties. The anti-inflammatory pathway was recently
elucidated through cytosolic nuclear factor E2-related factor 2 (Nrf2) activation and heme oxygenase (HO)-1 protein
expression. PV is a perennial herb and widely distributed in high-elevation mountain regions, such as the Tibetan
Plateau. In Tibetan traditional medicine, PV is usually used to boost the blood circulation to dissipate blood stasis.
Therefore, this study focused on how PV improves the vascular circulation and acts on vascular tissues.
Methods: In this study, we isolated aortas from Sprague-Dawley rats (male, weight about 250 ~ 350 g), and detected
the effects of PV on phenylephrine (PE)-induced contraction and cyclic guanosine 3′,5′-monophosphate (cGMP)
formation using aortic rings. In addition, human umbilical vein endothelial cells (HUVECs) were used to exam nitric
oxygen (NO) synthase (NOS) activity by directly measuring NO production in the culture medium. Endothelial (e) NOS
phosphorylation, and cytosolic Nrf2 and HO-1 expressions were measured using a Western blot analysis.
Results: PV dose-dependently relaxed PE-induced contractions in endothelial-intact but not -denuded aorta. The
concentration to produce 50% relaxation was 22.04 ± 1.77 μg/ml. PV-induced vasorelaxation was markedly blocked by
pretreatment with NG-nitro-L-arginine methyl ester (L-NAME), an NOS inhibitor, methylene blue (MB), a guanylyl cyclase
inhibitor, and hemoglobin, an NO scavenger. PV increased cGMP formation; however, this effect was also suppressed
by co-pretreatment with L-NAME, MB, hemoglobin, and Ca2+-free medium. In HUVECs, PV increased NO formation,
which was greatly attenuated by NOS inhibitors (L-NAME and L-NMMA) and by removing extracellular Ca2+ and
chelating intracellular Ca2+ with BAPTA-AM. In addition, PV promoted eNOS phosphorylation, Nrf2 degradation, and
HO-1 protein expression according to a Western blot analysis.
Conclusions: The results suggest that PV possesses vasorelaxing action in an endothelium-dependent manner and
works through activating Ca2+/calmodulin- dependent NO synthesis; when NO is released and then transferred to
smooth muscle cells, NO activates guanylyl cyclase and increases cGMP formation, ultimately resulting in vasorelaxation.
Thus, PV can be considered for application as a potential therapeutic approach for vascular-associated disorders.
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Polygonum viviparum L. (PV), a perennial herb, belongs
to the Polygonaceae family and is extensively distributed
in high-elevation mountain region, including the Alps,
Carpathians, Pyrenees, Caucasus Mountains, and the
Tibetan Plateau [1,2]. The common names of PV are
bistort, serpent-grass, and viviparous knotweed [3]. PV
is a perennial herb that arises from a short, thickened
rhizome that appears massive, distorted or uncinated.
The stem, which ranges from 10 to 30 cm in height and
terminates in a narrow, dense flowering spike, is simple,
erect and smooth and bears few leaves. The best survey
period lasts from approximately late June to early
September [4]. In traditional folk medicine, PV is used
to treat pharyngitis, dysentery, and gastrointestinal dis-
orders [5]. The rhizome and root of PV are reported to
possess excellent potency for curing bronchitis, piles,
wounds, ulcers, vomiting, and biliousness [6-8]. From
the literature over several decades, the major consti-
tuents of PV perhaps involve volatile oils [9], flavonoids,
flavone glycosides [10-13], gallic acid, saponins, and
tannins [14-16]. In addition, PV was demonstrated to
possess efficacious bioactive effects, including antibac-
terial [11,17], antiulcer [7], antioxidant [8,18], antitumor
[9,19], anti-inflammatory, and antiarthritic properties [20].
In our previous study, we demonstrated that PV has
anti-inflammatory actions in macrophages, possibly
acting through cytosolic nuclear factor E2-related fac-
tor 2 (Nrf2) activation to express heme oxygenase
(HO)-1 protein [4]. On the other hand, especially in
Tibetan traditional medicine, PV is usually used to
boost the blood circulation to dissipate blood stasis
[21]. Consequently, we wanted to determine how PV
improves the vascular circulation, and what effect PV
has on vascular tissues. In this study, the effect of
PV on the thoracic aorta isolated from rats was
examined.Methods
Plant material
Polygonum viviparum L. (PV) was obtained from Tibet.
Its authenticity was confirmed by Dr Shin-Ming Ku
(Herbarium, Biodiversity Research Center, Academia
Sinica, Taipei, Taiwan). The herb (PV 100 g) was ex-
tracted with 3 L of 2-propanol for 7 days, then the ex-
tract was filtered and centrifuged at 13 000 × g for
10 min. The extract supernatant was passed through a
0.22 μm sterile filter (Millipore, Billerica, MA, USA)
and first concentrated using a vacuum rotary evaporator
(Yamato, Tokyo, Japan) at 40°C. Normally, 8.76 g of
dried powder could be obtained from 100 g of PV. The
dried extract yield from the crude material was thus ap-
proximately 8.76% [4].Drugs and chemicals
Phenylephrine (PE), acetylcholine (Ach), NG-nitro-L-argi-
nine methyl ester (L-NAME), NG-monomethyl-L-arginine
acetate (L-NMMA), methylene blue (MB), hemoglobin
(Hb), and all chemicals of the Krebs solution were from
Sigma Chemical (St. Louis, MO, USA). Culture materials
(M199 medium, fetal bovine serum (FBS), and trypsin-
EDTA) were obtained from Life Technologies (Gibco,
Grand Island, NY, USA). Endothelial cell growth sup-
plement (ECGS) was purchased from Millipore (Billerica,
MA, USA). A cyclic guanosine 3′,5′-monophosphate
(cGMP) enzyme immunoassay kit was purchased from
R & D System (Minneapolis, MN, USA). All other agents
of cell culture were obtained from Sigma Chemical.
Preparation of rat aorta and tension recording ex vivo
Male Sprague-Dawley rats weighing about 250 ~ 350 g
were purchased from BioLASCO (Taipei, Taiwan). All
animal procedures were approved by the institutional
animal care and using committee of Taipei Medical
University. Animals were housed in polycarbonate
cages in a room at 22 ± 2°C on a 12-h light-dark cycle.
The procedure described by Hu et al. [22] was used to
isolate rat aortic rings. When the experiment began,
the rats were sacrificed by exsanguination from the ca-
rotid artery under lose consicousness by knocking me-
dulla; the thoracic aorta of rats was carefully removed,
and the fat and tissue were dissected away in normal
Krebs’ buffer at an adjusted pH of 7.4. The compo-
sition of this buffer was as follows: 118.5 mM NaCl,
4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4,
2.5 mM NaHCO3, 11.1 mM glucose, and 2.5 mM
CaCl2. The aorta was cut into rings about 5 mm long
in Krebs buffer which was constantly gassed with 95%
O2 + 5% CO2 at 37 ± 0.5°C. Two “L”-type stainless steel
hooks were inserted into the aortic lumen; one side
was fixed in the bottom bath and the other side was
connected to a force transducer using a cotton thread.
The aortic rings were equilibrated in Krebs buffer and
maintained under a 1-g tension for 60 ~ 90 min, with
three changes of buffer, before the experimental proce-
dures began. Contractions were recorded isometrically
via an iWorx FT-302 force transducer connected to an
iWorx 304 T recorder (iWorx System, Dover NH,
USA). In denuded aorta, the endothelium was removed
by rubbing with a cotton ball, and the absence of ACh-
induced relaxation was taken as an indicator of suc-
cessful denudation. After PE-induced contraction and
ACh-induced relaxation twice, PV (1, 3, 10, 30, 100
and 300 μg/ml) was treated after PE-induced con-
traction. The effects of PV as percentage of relaxa-
tion considering the maximum contraction elicited by
phenylephrine in preparations with at least 80% of re-
laxation to ACh.
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measurement
Rat aorta cGMP was analyzed using the method of
Kauffman et al. [23]. Briefly, the aorta was immediately
isolated from a rat, and cut into segments of about 20 mg/
tissue. First, the rat aortic rings were pre-incubated in
Krebs’ solution with 3-isobutyl-1-methylxathine (IBMX,
10 μM) for 5 min. Then, the aortic segments were placed
in Ca2+-free Krebs’ (EGTA 2.5 mM) buffer or pretreat-
ment inhibitors of L-NAME (50 μM) and MB (10 μM) for
10 min; then PV (100 μg/ml), sodium nitroprusside (SNP,
10 μM), and ACh (10 μM), as positive reagents, were
added for a further 2 min. After incubation with PV and
ACh, the aortic segments were rapidly frozen in liquid
nitrogen and stored at -80°C until homogenized in
0.5 ml of 10% trichloroacetic acid using a motor-driven
glass homogenizer. The homogenate was centrifuged at
10,000 × g for 5 min, and the supernatant was removed
and extracted three times with 1.5 ml of water-saturated
diethyl ether. The cGMP content was then assayed using
enzyme immunoassay kits (R & D System, Minneapolis,
MN, USA). Protein was measured by dissolving the
trichloroacetic acid precipitate in 1 ~ 2 ml of 5 N NaOH
followed by analysis using the method of Lowry et al. [24].
Cell culture
Human umbilical vein endothelial cells (HUVECs, con-
fluent second passage, P = 2) were purchased from the
Bioresource Collection and Research Center (BCRC),
Food Industry Research and Development Institute
(Hsinchu, Taiwan). Cells were grown at 37 ± 0.5°C in a hu-
midified 5% CO2 atmosphere in M199 medium (pH 7.4)
supplemented with 10% FBS, 25 U/ml heparin, 30 μg/ml
ECGS, 2 mM glutamine, 1.5 g/l NaHCO3, 10,000 units/l
of penicillin, and 100 mg/l of streptomycin. Culture plates
were coated with 1% gelatin before use. Confluent cells
were detached by trypsin-EDTA (0.05%: 0.02%, v/v), and
cells from passages 3 to 7 were used in the experiment.
Determination of nitric oxide (NO) production
HUVECs (5 × 105 cells/well) in 6-well plates were incu-
bated with or without various concentrations of PV (10,
30, and 100 μg/ml) and ACh (30 μM), as a positive
control, for 1 h. The supernatants of conditioned cells
were deproteinized by zinc-sulfate (30%, v/v) and passed
through a copper cadmium reduction column to reduce
NO3
- to NO2
- [25]. As an indicator of NO production, the
nitrite concentration in the culture medium was deter-
mined using the Griess reagent, as previously described
[26]. The culture supernatant (100 μl) was mixed with
100 μl of the Griess reagent (1% sulfanilamide and 0.1%
N-1-naphthyl ethylenediamine) for 10 min, and then the
chromophoric azo-derivative molecule’s absorbance was
measured in a microplate reader at 540 nm. Fresh culturemedium was used as the blank in all experiments. A range
of dilutions of sodium nitrite (NaNO2) was used to create
a standard curve with the amount of nitrite in each sam-
ple. The final NO production was expressed as μmol/l
(μM).
Preparation of total cell lysates
HUVECs (5 × 105 cells/well) in 6-well plates were incu-
bated with or without concentrations of PV (3, 10, and
30 μg/ml) or ACh (30 μM) for 0.5 or 24 h. Total cell
lysates were obtained using a lysis buffer (250 mM Tris-
HCl (pH 6.8), 1% Triton-100, 0.1% sodium dodecylsul-
fate (SDS), 1 mM Na3VO4, 1 mM EDTA, 5 mM sodium
fluoride, 1 mM PMSF, and 1 mg/ml leupeptin), and cell
debris was removed using a centrifuge at 10,000 × g for
10 min at 4°C and stored at -80°C until required. The
protein content of the cell lysates was determined using
the Bradford assay [27].
Western blot analysis
Equal amounts of cell lysates (30 μg) were electroblotted
onto a nitrocellulose membrane (Millipore), following
separation using 8%~ 12% SDS-polyacrylamide gel elec-
trophoresis (PAGE). The blot was probed using a primary
antibody against p-eNOS, total-eNOS (Millipore), Nrf2,
HO-1, and β-actin (Santa Cruz Biochemicals, Santa Cruz,
CA, USA). The intensity of each band was quantified
using density analysis software (Biospectrum 500 Imaging
System; Vision Works LS 6.5.2v, UK), and the density ra-
tio represented the relative intensity of each band against
controls in each experiment.
Data and statistical analyses
Results of all experiments are expressed as the mean ± S.E.
of multiple experiments (n ≥ 3). Data were compared
using a one-way analysis of variance (ANOVA) with
a post-hoc Bonferroni analysis when applicable, and
p values of < 0.05 were considered statistically significant.
Values of 50% effective concentration (EC50) were calcu-
lated and obtained from 5 regression lines; each regression
line was constructed from 3 ~ 5 points. Values of inhi-
bition of these points ranged 20% ~ 80%.
Results
PV-induced rat aortic relaxation
The vasorelaxing effect of PV was examined on PE
(3 μM)-precontracted rat aorta. Data show (Figure 1A)
that PE induced a rapid phasic contraction, followed by a
tonic contraction lasting for least 10 min in both intact
(endothelium-undamaged) and denuded (endothelium-
removed) aorta. Treatment with ACh (10 μM) caused
relaxation in intact but not denuded aorta. PV relaxed PE-
induced contractions in intact but not denuded aorta, as
shown in Figure 1B. As shown in Figure 1C, the relaxing
Figure 1 Relaxation effect of Polygonum viviparum L. (PV) in isolated rat thoracic aorta. The aorta was removed from a rat, and fat and
tissue were carefully dissected away in normal 37°C Krebs solution. Phenylephrine (PE) at 3 μM induced a transient phasic contraction followed
by tonic contraction, which lasted at least 10 min in intact or endothelial-denuded aorta. Acetylcholine (ACh) at 10 μM induced relaxation in
intact (A, upper trace) but not denuded (A, lower trace) aorta. PV at 100 μg/ml relaxed PE-precontracted intact (B, upper trace) but not denuded
(B, lower trace) aorta. (C) Concentration-response curve of vasorelaxation caused by PV on PE-precontracted rat intact aorta. Data are expressed
as the mean ± standard error of the mean (S.E.M.) (n≥ 5 animals per time point).
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dose-dependent manner. The EC50 value was 22.04 ±
1.77 μg/ml. The data indicated that PV might be respon-
sible for the endothelium-dependent vasorelaxation.
NO synthase (NOS), a guanylyl cyclase inhibitor, and an
NO scavenger suppressed PV-induced vasorelaxation
To elucidate endothelium-dependent PV-induced vasore-
laxation, whether NO is involved in PV-induced vasore-
laxation was further investigated. As shown in Figure 2,
10 μM ACh typically relaxed PE-induced vasocontraction
in endothelial-intact aorta (trace A). As shown trace B in
Figure 2, PV also exhibited vasorelaxation that was similar
to ACh’s typical action in intact aorta. Pretreatment with
50 μML-NAME (an NOS inhibitor) did not influence PE-
induced vasocontractions, but PV-induced vasorelaxation
was suppressed (trace C). Likewise, as shown in traces D
and E, PV-induced vasorelaxation was suppressed by
pretreatment with 5 μM Hb (an NO scavenger) and
10 μM MB (a guanylyl cyclase inhibitor).
Formation of cGMP was elevated by treatment with PV in
rat aorta
cGMP formation was measured to confirm whether gua-
nylyl cyclase activation participates in PV-induced vasore-
laxation in the rat aorta. Aortic rings were divided into 5
groups: intact, denuded, L-NAME pretreatment, MB pre-
treatment, and Ca2+-free Krebs buffer. As shown in
Table 1, the cGMP content of intact aorta significantly in-
creased after treatment with 10 μM ACh and 10 μM SNP.
However, ACh did not increase cGMP formation in thedenuded aorta. In this experimental model, we found that
PV’s effect was similar to that of Ach which induced an in-
crease in cGMP formation in intact but not denuded
aorta. In addition, increases in the PV-induced cGMP
content were suppressed by pretreatment with 50 μM
L-NAME, 10 μM MB, or Ca2+-free medium. Therefore,
these results further supported that NOS and guanylyl
cyclase activities, and extracellular Ca2+ are involved in
PV-induced vasorelaxation in the aorta.
PV increased NO production
To confirm NOS’s activity, NO production was directly
investigated in cultured medium of HUVECs using the
Griess reagent. As shown in Figure 3, NO production
dose-dependently increased after treatment with 3, 10, 30,
and 100 μg/ml PV in HUVECs for 1 h. ACh was used as a
positive control. As shown in Table 2, increases in
PV- and ACh-induced NO production were attenuated
by treatment with the NOS inhibitors, L-NAME and
L-NMMA [28]. In addition, after removal of intercellular
Ca2+ by treatment with EGTA or chelation of intracellular
Ca2+ by treatment with 1,2-bis (2-aminophenoxy) ethane-
N, N, N’, N’-tetraacetic acid (BAPTA-AM, increases) in
PV- and ACh-induced NO production were completely
inhibited. These results suggest that influx of extracellular
Ca2+ is indeed involved in the PV-activated NOS pathway.
PV induced eNOS phosphorylation, cytosolic Nrf2
degradation, and HO-1 protein expression
To elucidate the time coures of PV’s effect in HUVECs,
the cells were treated with various concentrations of PV
Figure 2 Effect of an nitric oxide (NO) synthase (NOS) inhibitor, NO scavenger, and guanylyl cyclase inhibitor on Polygonum viviparum
(PV)-induced relaxation in isolated rat aorta. Acetylcholine (ACh) at 10 μM and 100 μg/ml PV (traces A and B, respectively) were treated after
3 μM phenylephrine (PE)-induced vasocontraction reached the maximal force in intact aorta. Prior to the addition of 100 μg/ml PV, the aorta was
pretreated with 50 μM L-NAME (trace C), 5 μΜ hemoglobin (Hb) (trace D), and 10 μM methylene blue (MB) (trace E) for 6 min followed by the
addition of PE. Each experiments was conducted in aortic rings of at least 5 animals.
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by lysis buffer, and total cell lysates were collected; eNOS
phosphorylation, cytosolic Nrf2 degradation, and HO-1
protein levels were determined by a Western immunoblot




Control 0.53 ± 0.08 –
SNP 10 μM 3.45 ± 0.56* –
ACh 10 μM 3.21 ± 0.42* 0.60 ± 0.18
PV 100 μg/ml 3.18 ± 0.74* 0.57 ± 0.13
After pretreatment with 10 μM IBMX for 5 min, aortic segments were replaced in C
and methylene blue (MB) for 10 min and then sodium nitroprusside (SNP), acetylch
immersed in liquid nitrogen to stop the reaction. cGMP formation were measured.
than 5 individual experiments. –, not determined. * p < 0.05 indicates a significant dwith PV for 30 min resulted in marked phosphorylation of
eNOS in a dose-dependent manner, but the total eNOS
protein did not increase. However, the phospho-eNOS
level slightly decreased after treatment with PV for 24 h
compared to treatment with PV for 30 min. Treatmentine 3′, 5′-monophosphate (cGMP) formation by the rat
MP (pmol/mg protein)
-NAME 50 μM MB 10 μM Ca2+ free medium
– – –
– – –
0.70 ± 0.09 0.52 ± 0.12 0.45 ± 0.11
0.54 ± 0.09 0.66 ± 0.07 0.64 ± 0.04
a2+-free Krebs’ (2.5 mM EGTA) buffer or treatment with inhibitors of L-NAME
oline (ACh) and PV were added for another 2 min. The aortic rings were
Data are expressed as the mean ± standard error of the mean (S.E.M) of more
ifference from the control.
Figure 3 Polygonum viviparum (PV) promoted an increase in
nitric oxide (NO) production by human umbilical vein
endothelial cells (HUVECs). Cells were treated with 3, 10, 30, and
100 μg/ml PV for 1 h. Medium was then collected for NO detection
using the Griess reagent. Data are expressed as the mean ± standard
error of the mean (S.E.M.) for more than 5 individual determinations.
Treatment with acetylcholine (ACh) was used as a positive control.
* p < 0.05, ** p < 0.01, significantly different from the control.
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PV increased cytosolic Nrf2 degradation and HO-1 pro-
tein expression. As shown in Figure 4B, it is clear that
the density ratio of phosphor-eNOS, cytosolic Nrf2 deg-
radation and HO-1 were elevated by PV in the quantita-
tive determination.
Discussion
In this study, effects of PV were investigated on rat aorta
ex vivo and on HUVECs in vitro. We explored the poten-
tial involvement of eNOS activation in vasorelaxation by
PV. First, we found that PV dose-dependently induced
vasorelaxation in PE-precontracted aorta in an endothe-
lium-dependent manner (Figure 1). It is well known that
NO was first discovered in 1980 as an endothelium-Table 2 Effects of Polygonum viviparum (PV) on nitric
oxide (NO) production by human umbilical vein
endothelial cells (HUVECs)
Nitrite [μM]/5 × 105 cells
Blank PV (30 μg/ml) ACh (30 μM)
Blank 0.378 ± 0.559 8.445 ± 0.878 7.412 ± 0.661
L-NAME (50 μM) 0.631 ± 0.518 2.073 ± 0.244** 1.066 ± 0.165##
L-NMMA (50 μM) 0.476 ± 0.483 2.232 ± 0.383** 1.154 ± 0.397##
Ca2+-free 0.505 ± 0.442 0.668 ± 0.324** 0.964 ± 0.352##
BAPTA-AM (20 μM) 0.432 ± 0.378 0.584 ± 0.460** 0.511 ± 0.369##
HUVECs were incubated with PV and acetylcholine (ACh) for 1 h, and then the
culture medium was collected for NO detection with the Griess reagent.
Ca2+-free medium contained 2.5 mM EGTA. BAPTA-AM chelates intracellular
Ca2+. Data are expressed as the mean ± standard error of the mean (S.E.M) for
more than 5 individual experiments. ** p < 0.01 indicates a significant difference
from PV alone. ## p < 0.01 indicates a significant difference from ACh alone.derived relaxing factor [29] and as a key control of
vascular homeostasis [30]. NO is a soluble gas and is
synthesized from the amino acid L-arginine by a family of
enzymes called NOSs [31]. NOS activity can be inhibited
by NOS blockers through a mechanism that competes
with L-arginine for the substrate-binding site on NOS,
such as L-NAME and L-NMMA [32,33], and the NO is
caught by NO scavengers, such as Hb [34]. In blood ves-
sels, eNOS converts L-arginine to L-citrulline and NO.
Afterwards, NO can diffuse into both the vessel lumen
and wall which activates soluble guanylate cyclase, leading
to the intracellular accumulation of cGMP [35]. However,
soluble guanylate cyclase activity is inhibited by some
agents, such as MB [32]. In this study, we found that the
vasorelaxation by PV could be suppressed by pretreatment
with an NOS inhibitor (L-NAME), a guanylyl cyclase
inhibitor (MB), and an NO scavenger (Hb) (Figure 2).
These results indicate that the formation of NO and
cGMP respectively involves activation of NOS and guany-
lyl cyclase. Further direct evidence was provided by mea-
suring cGMP in the rat aorta (Table 1). Results showed
that PV increased cGMP accumulation, and this effect
was suppressed by pretreatment with L-NAME and MB
(Figure 5).
Normally, homeostasis of the vessel wall is regulated by
endothelial cells that are able to relax vascular smooth
muscle cells. Under general physiological conditions, the
dominant NOS isoform in the vasculature is eNOS [36].
In order to elucidate whether or not the effect of PV on
the rat aorta is through activating eNOS-caused vasore-
laxation, we further investigated the effects of PV on
HUVECs. We found that NO production significantly
increased after treatment with PV in HUVECs, and this
increased NO production was inhibited by pretreatment
with L-NAME and L-NMMA. In addition, we demon-
strated that PV could promote eNOS phosphorylation,
cytosolic Nrf2 degradation, and HO-1 protein expression
(Figure 4) by HUVECs. It is well known that eNOS can be
regulated by multiple phosphorylation sites at tyrosine,
serine, and threonine residues [36]. Fulton et al. reported
that phosphorylation of Tyr83 regulates the ability of
eNOS to produce NO [37]. Heiss et al. reported that
activating Nrf2 can elevate the bioavailability of NO by
triggering eNOS phosphorylation and reducing eNOS
protein expression by HUVECs [38]. The nuclear factor
E2-related factor 2 (Nrf2) play a critical role by interacting
with cognate DNA-binding domains in the HO-1 pro-
moter to up-regulate ho-1 gene transcription [39]. Cyto-
plasmic Nrf2 is bound to the Kelch-like ECHassociated
protein 1 under general conditions; however, the Nrf2/
Keap1 complex can be disrupted by somecompounds,
which allows the translocation of Nrf2 into the nuclei
[40]. Previously, we reported that PV can activate the
Nrf2/HO-1 pathway to defend against lipopolysaccharide
Figure 4 Effect of Polygonum viviparum (PV) on endothelial nitric oxide (NO) synthase (eNOS) phosphorylation, cytosolic nuclear factor
E2-related factor 2 (Nrf2) degradation, and heme oxygenase (HO)-1 activation. (A) Human umbilical vein endothelial cells (HUVECs) were
treated with PV (at the indicated concentrations) for 0.5 or 24 h. Total proteins (30 μg) were analyzed on an 8% SDS-PAGE with an antibody
specific of eNOS Ser-1177; and analyzed on 10% SDS-PAGE with an antibody specific of Nrf2 and HO-1. (B) The relative density was calculated as
the ratio of eNOS (phosphor form) expression to eNOS (total form) expression. In addition, the relative density was calculated as the ratio of Nrf2
degradation and HO-1 expression to β-actin expression. Each electrophoretogram is representative of the results from more than 5 individual
experiments. * p < 0.05, # p <0.05, ξξ p < 0.01, significantly different from the control.
Figure 5 The flow chart of endothelium-dependent mediator of vasorelaxation by PVin rat thoracic. PV increase vessel diameter in an
endotheliumdependent manner by stimulating production of nitric oxide. cGMP (cyclic guanosine monophosphate); GC (guanylyl cyclase);
GTP (guanosine triphosphate); NO (nitric oxide); NOS (nitric oxide synthase).
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provide evidence that PV can induce Nfr2 activation and
further promote eNOS phosphorylation by HUVECs. In
the context of the cardiovascular system, knowledge that
Nrf2 possesses antioxidant and anti-inflammatory charac-
ters can be of benefit in the onset of endothelial dys-
function [41]. Ideally, eNOS is sufficiently phosphorylated
to produce NO, and it then has a protective physiological
function and reaches its signaling target, mainly activating
soluble guanylyl cyclase and eliciting cGMP production in
the vasculature [42].
Conclusions
Results from this study showed that PV can relax PE pre-
contractions in an endothelium-dependent manner in
the rat aorta. The fact that activating Ca2+/calmodulin-
dependent NO synthesis signaling plays a critical role in
the regulation of PV-induced vasorelaxation supports our
results. Overall, we provide possible mechanistic insights
of PV in an approach for therapy of vascular-associated
disorders.
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